



EUROPEAN UNION OF MEDICAL SPECIALISTS (UEMS)
EUROPEAN ACCREDITATION COUNCIL FOR CME (EACCME®)

RUE DE L'INDUSTRIE 24, BE- 1040 BRUSSELS
 T + 32 2 649 51 64
eaccme.uems.eu - accreditation@uems.eu

Conflict of Interest Disclosure Form

(to be completed by Scientific/Organizing Committee Members)

NAME: Ashish M. Kamat

AFFILIATION: The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

In accordance with criterion 13 of document UEMS 2023/07 "EACCME® Criteria for the Accreditation of

Live Educational Events (LEEs)", all declarations of perceived or actual conflicts of interest for the last 3 years, whether due to a financial or other relationship, must be provided to the EACCME® upon submission of the application. COI declarations signed more than 6 months before the date of the event will not be accepted. Declarations must be made available online on the event website of the LEE. Declarations must include whether any fee, honorarium or arrangement for re-imbursement of expenses in relation to the LEE has been provided.

DISCLOSURE

☐ I have no potential conflict of interest to report

☒ I have the following potential conflict(s) of interest to report

Type of affiliation / financial interest	Name of commercial company
---	-----------------------------------

Receipt of grants/research supports:

Receipt of honoraria or consultation fees:

Participation in a company sponsored speaker's bureau:

Stock shareholder:

Spouse/partner:

Other support (please specify):

AMK has received research funding from FKD Therapies (now Ferring), the Patient-Centered Outcomes Research Institute (PCORI), Photocure, Seagen, EnGene, Arquer Diagnostics, and SWOG. AMK has also received advisory board or consulting fees from Astellas Pharma, Atonco Pharma, Biological Dynamics, Bristol-Myers Squibb, CG Oncology, Cystotech, Eisai, EnGene, Ferring, Genentech, Imagin Medical, ImmunityBio, Invax, Incyte, Janssen, Medac, Merck, Nonagen Bioscience, Pfizer, Photocure, Protara Therapeutics, Roche, Seagen, Sesen Bio (now Carisma), Theralase, Urogen Pharma, US Biotest, Valar Labs, and Vivet Therapeutics. AMK holds a joint patent with MD Anderson Cancer Center for CyPRIT

(Cytokine Predictors of Response to Intravesical Therapy). AMK also holds/recently held leadership or fiduciary roles in the International Bladder Cancer Group (IBCG), European Urology Oncology, the Journal of Urology, UroToday, American Urological Association (AUA), and World Bladder Cancer Patient Coalition.

Grants or Contracts

- FKD Therapies (now Ferring)
- Patient-Centered Outcomes Research Institute (PCORI)
- Photocure
- Seagen
- EnGene
- Arquer Diagnostics
- SWOG

Advisory Board/Consulting Fees

- Astellas Pharma
- Atonco Pharma
- Biological Dynamics
- Bristol-Myers Squibb
- CG Oncology
- Cystotech
- Eisai
- EnGene
- Ferring
- Genentech
- Imagin Medical
- ImmunityBio
- Imvax
- Incyte
- Janssen (J&J)
- Medac
- Merck
- Nonagen Bioscience
- Pfizer
- Photocure
- Protara Therapeutics
- Roche
- Seagen
- Sesen Bio (now Carisma)
- Theralase
- Urogen Pharma
- US Biotest
- Valar Labs
- Vivet Therapeutics

Patents

- CyPRIT (Cytokine Predictors of Response to Intravesical Therapy) - Joint patent with MD Anderson Cancer Center # 00043705

Leadership or fiduciary role in other board, society, committee or advocacy group

- International Bladder Cancer Group (IBCG)
- European Urology Oncology
- Journal of Urology
- UroToday
- World Bladder Cancer Patient Coalition

- American Urological Association

Signature:

Signed by:

Ashish Kamat

4DEB8C73741D4FD

Date: 16 December 2025

UEMS_{aisbl} – Union Européenne des Médecins Spécialistes

VAT n° BE 0469.067.848 RPM Bruxelles-Brussels

EU Transparency Register ID 219038730914-92